Asia Pacific Branded Generics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-Inflammatory, and Others), Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies, and Drug Stores), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Antihypertensive, Lipid-Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptic, and Others), and Formulation Type (Oral, Parenteral, Topical, and Others)
The branded generics market in Asia Pacific is expected to grow from US$ 71.45 billion in 2022 to US$ 130.39 billion by 2028; it is estimated to grow at a CAGR of 10.5% from 2022 to 2028.
A Scientific Electronic Library Online (SciELO) report states that promoting branded generics constitutes a core instrument for countries' national pharmaceutical policies, ultimately reducing drug expenditure with expanding healthcare access. In November 2008, the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India launched Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) to make quality generic medicines available at affordable prices. Under the scheme, dedicated outlets known as Janaushadhi Kendras offered generic medicines at affordable prices. As of 2021, 8,012 Janaushadhi Kendras were functional across the country. Moreover, a Food and Drug Administration (FDA) report states that if the FDA approves most branded generics, it can drop the costs of medicines. Generally, multiple generic drugs for the same product create competition in the market. For example, a single generic competitor results in price reductions of up to 30%, while five competing generics are associated with a price drop of nearly 85%.
The WHO estimates that about 65% of the Indian population lacks regular access to essential medicines despite India being one of the largest manufacturers and suppliers of generic drugs. The price of generic drugs procured by the government in bulk is less than the price paid for a branded drug by an individual consumer. It can be lowered to 2% of the retail price of a branded drug. Therefore, the provision related to free drugs acts as one of the most important interventions responsible for mitigating the burden on healthcare costs. One of the targets of the proposed Sustainability Development Goals of Indian Government is to achieve universal healthcare coverage, including financial risk protection; access to quality essential health care services; and access to safe, effective, quality, and affordable essential medicines. Therefore, the rise in government initiatives for promoting branded generics drives the growth of the Asia Pacific branded generics market.
By introducing new features and technologies, vendors in the Asia Pacific branded generics market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market at a good CAGR during the forecast period.
Asia Pacific Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
Asia Pacific Branded Generics Market Segmentation
Asia Pacific branded generics market is segmented into therapeutic application, distribution channel, drug class, formulation type and country. The therapeutic application segment of the Asia Pacific branded generics market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, and analgesics and anti-inflammatory. In 2022, the others segment held the largest share of the market, by therapeutic application. The Asia Pacific branded generics market, by distribution channel is hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies segment is likely to hold the largest share of the market in 2022. The Asia Pacific branded generics market, by drug class is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. The others segment is likely to hold the largest share of the market in 2022. The Asia Pacific branded generics market, based on formulation type is segmented into oral, parenteral, topical, and other. In 2022, the oral segment held the largest share of the market, by formulation type. Based on country, the Asia Pacific branded generics market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China held the largest market share in 2022.
Aspen Holdings, AstraZeneca, Bausch Health (Valeant Pharmaceuticals), Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Hetero, Lupin, Mylan N.V., Par Pharmaceuticals, Sandoz International Gmbh, Sanofi, and Teva Pharmaceutical Industries Ltd. are among the leading companies in the branded generics market operating in this region.
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Branded Generics Market – By Therapeutic Application
1.3.2 APAC Branded Generics Market – By Distribution Channel
1.3.3 APAC Branded Generics Market – By Drug Class
1.3.4 APAC Branded Generics Market – By Formulation Type
1.3.5 APAC Branded Generics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Branded Generics Market – Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.2.1 Experts Opinion
5. APAC Branded Generics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Branded Generics Becoming Popular
5.1.2 Branded Generics Being Promoted by Various Government Initiatives
5.2 Market Restraints
5.2.1 Switching Brands, Poorer Clinical Outcomes and Adverse Effects of Generic Medications
5.3 Market Opportunities
5.3.1 Product Differentiation Providing New Opportunities
5.4 Future Trends
5.4.1 Encouraging Utility of Branded Generics by Healthcare Providers and Professionals
5.5 Impact Analysis
6. Branded Generics Market– APAC Analysis
6.1 APAC Branded Generics Market Revenue Forecast and Analysis
6.2 APAC Branded Generics Market, By Country - Forecast and Analysis
7. APAC Branded Generics Market Revenue and Forecast To 2028– by Therapeutic Application
7.1 Overview
7.2 APAC Branded Generics Market, By Therapeutic Application: Market Revenue and Forecast Analysis (US$ Billion)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology Market Revenue and Forecast to 2028 (US$ Billion)
7.4 Cardiovascular Diseases
7.4.1 Overview
7.4.2 Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.5 Diabetes
7.5.1 Overview
7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
7.6 Neurology
7.6.1 Overview
7.6.2 Neurology Market Revenue and Forecast to 2028 (US$ Billion)
7.7 Gastrointestinal Diseases
7.7.1 Overview
7.7.2 Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.8 Dermatology Diseases
7.8.1 Overview
7.8.2 Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.9 Analgesics and Anti-Inflammatory
7.9.1 Overview
7.9.2 Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
7.10 Others
7.10.1 Overview
7.10.2 Others Market Revenue and Forecast to 2028 (US$ Billion)
8. APAC Branded Generics Market Analysis and Forecast to 2028 by Distribution Channel
8.1 APAC Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
8.2 Hospital Pharmacies
8.2.1 Overview
8.2.2 Hospital Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.3 Retail Pharmacies
8.3.1 Overview
8.3.2 Retail Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.4 Online Pharmacies
8.4.1 Overview
8.4.2 Online Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.5 Drug Stores
8.5.1 Overview
8.5.2 Drug Stores: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9. APAC Branded Generics Market Analysis and Forecast to 2028 by Drug Class
9.1 APAC Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
9.2 Alkylating Agents
9.2.1 Overview
9.2.2 Alkylating Agents: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.3 Antimetabolites
9.3.1 Overview
9.3.2 Antimetabolites: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.4 Hormones
9.4.1 Overview
9.4.2 Hormones: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.5 Anti-hypertensive
9.5.1 Overview
9.5.2 Anti-hypertensive: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.6 Lipid Lowering Drugs
9.6.1 Overview
9.6.2 Lipid Lowering Drugs: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.7 Anti-Depressants
9.7.1 Overview
9.7.2 Anti-Depressants: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.8 Anti-psychotics
9.8.1 Overview
9.8.2 Anti-psychotics: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.9 Anti-epileptic
9.9.1 Overview
9.9.2 Anti-epileptic: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.10 Others
9.10.1 Overview
9.10.2 Others: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
10. APAC Branded Generics Market Analysis and Forecast to 2028 – by Formulation Type
10.1 Overview
10.2 APAC Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Billion)
10.4 Parenteral
10.4.1 Overview
10.4.2 Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
10.5 Topical
10.5.1 Overview
10.5.2 Topical Market Revenue and Forecast to 2028 (US$ Billion)
10.6 Others
10.6.1 Overview
10.6.2 Others Market Revenue and Forecast to 2028 (US$ Billion)
11. APAC Branded Generics Market Revenue and Forecasts to 2028 Country Analysis
11.1 Overview
11.1.1 APAC: Branded Generics Market Revenue and Forecasts to 2028, By Country (%)
11.1.1.1 Japan: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.1.1 Overview
11.1.1.1.2 Japan: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.1.3 Japan: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.1.1.1.4 Japan: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.1.1.1.5 Japan: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.1.6 Japan: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2 China: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.2.1 Overview
11.1.1.2.2 China: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.2.3 China: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.1.1.2.4 China: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.1.1.2.5 China: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2.6 China: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3 India Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.3.1 Overview
11.1.1.3.2 India: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.3.3 India: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.1.1.3.4 India: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.1.1.3.5 India: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3.6 India: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4 South Korea: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.4.1 Overview
11.1.1.4.2 South Korea: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.4.3 South Korea: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.1.1.4.4 South Korea: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.1.1.4.5 South Korea: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4.6 South Korea: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.5 Australia: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.5.1 Overview
11.1.1.5.2 Australia: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.1.1.5.3 Australia: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.1.1.5.4 Australia: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.1.1.5.5 Australia: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.5.6 Australia: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6 Rest of APAC: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6.1 Overview
11.1.1.6.2 Rest of APAC: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6.3 Rest of APAC: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.1.1.6.4 Rest of APAC: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.1.1.6.5 Rest of APAC: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6.6 Rest of APAC: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
12. Branded Generics Market–Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 MYLAN N.V.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bausch Health Companies Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Lupin
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Sanofi
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 ASTRAZENECA PLC.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Par Pharmaceuticals, INC
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Sandoz International GMBH
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Aspen Holdings
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Hetero
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Japan: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
Table 2. Japan: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
Table 3. Japan: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 4. Japan: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
Table 5. China: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
Table 6. China: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
Table 7. China: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 8. China: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
Table 9. India: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
Table 10. India: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
Table 11. India: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 12. India: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
Table 13. South Korea: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
Table 14. South Korea: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
Table 15. South Korea: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 16. South Korea: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
Table 17. Australia: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
Table 18. Australia: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
Table 19. Australia: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 20. Australia: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
Table 21. Rest of APAC: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
Table 22. Rest of APAC: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
Table 23. Rest of APAC: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 24. Rest of APAC: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)
Table 25. Organic Developments Done By Companies
Table 26. Inorganic Developments Done By Companies
Table 27. Glossary of Terms
LIST OF FIGURES
Figure 1. APAC Branded Generics Market Segmentation
Figure 2. APAC Branded Generics Market, By Country
Figure 3. APAC Branded Generics Market Overview
Figure 4. Others Segment Held Largest Share of Drug Class Segment in APAC Branded Generics Market
Figure 5. India is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. APAC: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints on APAC Branded Generics Market
Figure 9. APAC Branded Generics Market – By Country Forecast and Analysis – 2019 - 2028
Figure 10. APAC Branded Generics Market, By Therapeutic Application: Market Analysis and Forecast 2022 and 2028 (%)
Figure 11. APAC Oncology Market Revenue and Forecast to 2028 (US$ Billion)
Figure 12. APAC Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
Figure 13. APAC Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
Figure 14. APAC Neurology Market Revenue and Forecast to 2028 (US$ Billion)
Figure 15. APAC Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
Figure 16. APAC Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
Figure 17. APAC Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
Figure 18. APAC Others Market Revenue and Forecast to 2028 (US$ Billion)
Figure 19. APAC Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
Figure 20. APAC Hospital Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 21. APAC Retail Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 22. APAC Online Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 23. APAC Drug Stores: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 24. APAC Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
Figure 25. APAC Alkylating Agents: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 26. APAC Antimetabolites: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 27. APAC Hormones: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 28. APAC Anti-hypertensive: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 29. APAC Lipid Lowering Drugs: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 30. APAC Anti-Depressants: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 31. APAC Anti-psychotics: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 32. APAC Anti-epileptic: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 33. APAC Others: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 34. APAC Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
Figure 35. APAC Oral Market Revenue and Forecast to 2028 (US$ Billion)
Figure 36. APAC Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
Figure 37. APAC Topical Market Revenue and Forecast to 2028 (US$ Billion)
Figure 38. APAC Others Market Revenue and Forecast to 2028 (US$ Billion)
Figure 39. APAC Branded Generics Market Overview, by Country (2022)
Figure 40. APAC: Branded Generics Market Revenue and Forecasts to 2028, By Country (%)
Figure 41. Japan: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
Figure 42. China: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
Figure 43. India: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
Figure 44. South Korea: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
Figure 45. Australia: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
Figure 46. Rest of APAC: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 47. Growth Strategies Done by the Companies in the Market (%)
- Aspen Holdings
- AstraZeneca
- Bausch Health (Valeant Pharmaceuticals)
- Dr. Reddy's Laboratories Inc.
- GlaxoSmithKline plc
- Hetero
- Lupin
- Mylan N.V.
- Par Pharmaceuticals
- Sandoz International Gmbh
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific branded generics market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific branded generics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the branded generics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution